| Prev Close | 136.79 |
| Day Low/High | 133.58 / 137.75 |
| 52 Wk Low/High | 133.20 / 199.00 |
Seagen, Inc. (SGEN)
137.09
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 182.86B |
| Market Cap | 25.01B |
| P/E Ratio | 69.22 |
| Div & Yield | N.A. (N.A) |
Latest News
Is It Time to Sell Seagen Shares?
Let's take a fresh look at the charts and indicators.
Nasty Mix, Lockdown Anxiety, Measuring the Fears, Super Bowl of Tech Earnings
In plain speak, they ran for the exits on Wednesday, This week has been a period of intense institutional distribution.
Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors?
BMY's announced acquisition of MyoKardia for $13B comes less than a year after its purchase of Celgene.
Seattle Genetics Hits New Highs and a Strategy Adjustment Is Needed
The charts and indicators of SGEN are looking healthy.
Biotech M&A Picks Up: Lessons for Investors and Potential Targets
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
Jim Cramer: Is This Market Undervalued?
Stocks are reasonable. Or even cheap. There will be more sell-offs ahead but remember this day and do not get too negative.
How About That Merck and Seattle Genetics Deal?
I am long Merck, not Seattle Genetics, though the one to own now is obviously SGEN.
Spate of Deal News Juices Start of This Week's Trading
We've become accustomed lately to gap-up opens on Mondays, but some fresh acquisition agreements are helping drive this Monday's action.
Here's My Take on Seattle Genetics
The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.
Seattle Genetics Soars on Cancer Drugs: Here's How to Play the Stock
This biotech is on the front lines of oncology treatments.
Seattle Genetics: Where's This Biotech Stock Headed From Here?
Time to check the charts and indicators.
6 Top Biopharmaceutical Stock Picks You Should Know About
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Seattle Genetics Has a Rally in Its DNA
Here's how to play this biotech stock.
Grab a Coffee, We've Got a Lot to Talk About Today!
Good morning folks! As Doug heads off on vacation (something I'll be doing on Saturday myself), I'm sitting in today for him, and I'll be doing so again right before his return. We're in the second real week of the June-quarter earnings season, and ...
Seattle Genetics Struggles as Other Biotech Stocks Rise
Market is pretty much where it has been all day, nicely positive across the board. Biotech up nearly 2% on the day. Gilead Sciences, Inc. , and Celgene Corp. , are two large caps on the move for reasons we covered in previous posts. The Bristol-Myer...
Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers
The Menlo Park, Calif.-based firm on Thursday reported third-quarter results and said it has hired Cowen to help with evaluating potential transactions.
Activist Investor to Block Partnership of Immunomedics and Seattle Genetics
The largest shareholder of Immunomedics, VenBio, asks for an injunction against its partnership with Seattle Genetics.
Midday Report: Stocks Higher as Consumer Confidence, Housing Prices Rise
Stocks were up midday Tuesday as the Dow moves toward the 20,000 milestone and consumer confidence increases.
Intermediate Trade: Seattle Genetics
Selling in SGEN has created a huge upside vacuum; take advantage with this vertical call spread strategy.
Intermediate Trade: Seattle Genetics
This biotech is not as high-risk a play as you might think.
CLOSED: Intermediate Trade: Seattle Genetics
The trade is once again the out-of-the-money, bullishly biased vertical call spread.
Dig Into Grand Canyon, Weatherford Shares Says Thornburg Value Manager
Shares of Grand Canyon Education (LOPE) have fallen over 18% so far in 2015, but they have still outperformed the rest of the beleaguered for-profit education sector.
